Research programme: lactose intolerance therapeutic - CelprogenAlternative Names: CEP 801
Latest Information Update: 05 May 2015
At a glance
- Originator Celprogen
- Class Gene-directed enzyme-prodrug therapies
- Mechanism of Action Carbohydrate metabolism stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lactose intolerance
Most Recent Events
- 23 Apr 2015 Preclinical trials in Lactose intolerance in USA (Unspecified) before April 2015